Genomic Cancer Testing Market Size is valued at USD 18.47 billion in 2024 and is predicted to reach USD 86.13 billion by the year 2034 at a 16.8% CAGR during the forecast period for 2025-2034.
Genomic cancer testing examines the DNA of cancer cells to detect hereditary abnormalities. This data informs individualized treatment strategies, such as precision medicines, tailored to the tumour's specific genetic characteristics. It offers predictive information, facilitates involvement in clinical studies, and assists in tracking the progression of cancer over time. This methodology improves precision medicine in oncology by customizing therapies based on the specific genetic traits of each individual.
The increasing demand for diagnostics, improvements in technologically advanced and cost-effective diagnostic technologies, and investments in the biotech and pharmaceutical industries are driving market expansion. Furthermore, the advancement of genetics in cancer care is aided by considerable research and development efforts to establish novel treatment techniques.
However, during the first stages of the pandemic, ordinary healthcare services, such as cancer screenings and elective operations, were disrupted. As a result, cancer diagnosis and treatments were delayed, potentially reducing demand for genetic cancer testing. However, telemedicine and virtual consultations became more popular during the pandemic to limit the danger of virus transmission. This transition influenced how people interacted with healthcare practitioners, including conversations regarding genomic testing possibilities.
The Genomic Cancer Testing Market is segmented based on test type, cancer type, technology, end-user, biomarker type, service provider, application, and testing setting. The product segment comprises Genomic Profiling Tests, Liquid Biopsy Tests, Companion Diagnostic Tests, Pharmacogenomic Tests, Hereditary Cancer Tests, and Other specialized genomic tests. The cancer type segment includes Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Melanoma, Leukemia, Lymphoma, and Other specific cancer types. By technology, the market is segmented into Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), Microarray, Immunohistochemistry (IHC), and Other genomic testing technologies. The end-user segment includes Hospitals, Diagnostic Laboratories, Academic and Research Institutions, Cancer Centers, and Other healthcare providers. The biomarker type segment is segmented into Genetic Biomarkers, Protein Biomarkers, Molecular Biomarkers, and Epigenetic Biomarkers. The service provider segment includes Diagnostic Laboratories, Biotechnology Companies, Pharmaceutical Companies, and Contract Research Organizations (CROs). By application, the market is segmented into Targeted Therapy Selection, Disease Monitoring, Prognostic Testing, Companion Diagnostics, Risk Assessment, and Pharmacogenomic Testing. The testing setting segment includes In-House Testing and Outsourced Testing.
The Genomic Profiling Tests category is expected to hold a major share of the global Genomic Cancer Testing Market in 2022. The genomic cancer testing market, which is primarily driven by genomic profiling tests, is impacted by a number of variables that contribute to the growing adoption and demand for these tests. Genomic profiling entails examining the whole collection of genes in a person's tumour in order to understand the genetic changes that cause cancer. Genomic technology developments, such as next-generation sequencing (NGS), have considerably increased genomic profiling studies' efficiency, speed, and cost-effectiveness. This has aided in the widespread use of these tests in clinical settings.
The Breast Cancer segment is projected to grow at a rapid rate in the global Genomic Cancer Testing Market. Various factors contribute to the increased use and demand for genetic testing specifically customized for breast cancer patients, driving the genomic cancer testing market for breast cancer. In breast cancer, genomic testing provides information about specific molecular traits, allowing doctors to make more informed treatment decisions. Identifying targeted medicines for tumours with specific genetic alterations, such as HER2-positive breast cancer.
The North America Genomic Cancer Testing Market is expected to record the maximum market revenue share in the near future, owing to the high level of public awareness regarding cancer genomic testing in the United States and Canada. Because of the rise in the prevalence of breast cancer in BENELUX, Europe is the second most fastest growing region for the cancer genomic testing industry. In addition, Asia Pacific is estimated to grow rapidly in the global Genomic Cancer Testing Market because of an increase in the number of obese patients in nations such as India, China, and Japan. Because of a lack of awareness among people regarding cancer genomic testing, Latin America, the Middle East, and Africa are the least profitable regions for the cancer genomic testing business.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 18.47 Bn |
|
Revenue Forecast In 2034 |
USD 86.13 Bn |
|
Growth Rate CAGR |
CAGR of 16.8% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Test Type, By Cancer Type, By Technology, By End-User, By Biomarker Type, By Service Provider, By Application, By Testing Setting |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Illumina, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Foundation Medicine, Inc. (Roche), Invitae Corporation, NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Genomic Health, Inc. (Exact Sciences Corporation), Caris Life Sciences, ArcherDX, Inc. (Invitae Corporation), Guardant Health, Inc., Personal Genome Diagnostics Inc., Biocept, Inc., and Tempus Labs, Inc., Danaher, PerkinElmer, Agilent Technologies, Inc., Quest Diagnostics, Luminex Corporation |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Genomic Cancer Testing Market Snapshot
Chapter 4. Global Genomic Cancer Testing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Technology Estimates & Trend Analysis
5.1. By Technology, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Technology:
5.2.1. Next-Generation Sequencing (NGS)
5.2.2. Polymerase Chain Reaction (PCR)
5.2.3. Fluorescence In Situ Hybridization (FISH)
5.2.4. Microarray
5.2.5. Immunohistochemistry (IHC)
5.2.6. Other genomic testing technologies
Chapter 6. Market Segmentation 2: By Test Type Estimates & Trend Analysis
6.1. By Test Type & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Test Type:
6.2.1. Genomic Profiling Tests
6.2.2. Liquid Biopsy Tests
6.2.3. Companion Diagnostic Tests
6.2.4. Pharmacogenomic Tests
6.2.5. Hereditary Cancer Tests
6.2.6. Other specialized genomic tests
Chapter 7. Market Segmentation 3: By Cancer Type Estimates & Trend Analysis
7.1. By Cancer Type & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Cancer Type:
7.2.1. Breast Cancer
7.2.2. Lung Cancer
7.2.3. Colorectal Cancer
7.2.4. Prostate Cancer
7.2.5. Ovarian Cancer
7.2.6. Melanoma
7.2.7. Leukemia
7.2.8. Lymphoma
7.2.9. Other specific cancer types
Chapter 8. Market Segmentation 4: By End-User Estimates & Trend Analysis
8.1. By End-User & Market Share, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-User:
8.2.1. Hospitals
8.2.2. Diagnostic Laboratories
8.2.3. Academic and Research Institutions
8.2.4. Cancer Centers
8.2.5. Other healthcare providers
Chapter 9. Market Segmentation 5: By Biomarker Type Estimates & Trend Analysis
9.1. By Biomarker Type & Market Share, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Biomarker Type:
9.2.1. Genetic Biomarkers
9.2.2. Protein Biomarkers
9.2.3. Molecular Biomarkers
9.2.4. Epigenetic Biomarkers
Chapter 10. Market Segmentation 6: By Service Provider Estimates & Trend Analysis
10.1. By Service Provider & Market Share, 2024 & 2034
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Service Provider:
10.2.1. Diagnostic Laboratories
10.2.2. Biotechnology Companies
10.2.3. Pharmaceutical Companies
10.2.4. Contract Research Organizations (CROs)
Chapter 11. Market Segmentation 7: By Application Estimates & Trend Analysis
11.1. By Application & Market Share, 2024 & 2034
11.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
11.2.1. Targeted Therapy Selection
11.2.2. Disease Monitoring
11.2.3. Prognostic Testing
11.2.4. Companion Diagnostics
11.2.5. Risk Assessment
11.2.6. Pharmacogenomic Testing
Chapter 12. Market Segmentation 8: By Testing Setting Estimates & Trend Analysis
12.1. By Testing Setting & Market Share, 2024 & 2034
12.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Testing Setting:
12.2.1. In-House Testing
12.2.2. Outsourced Testing
Chapter 13. Genomic Cancer Testing Market Segmentation 9: Regional Estimates & Trend Analysis
13.1. North America
13.1.1. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Technology, 2021-2034
13.1.2. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Test Type, 2021-2034
13.1.3. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Cancer Type, 2021-2034
13.1.4. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By End-User, 2021-2034
13.1.5. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Biomarker Type, 2021-2034
13.1.6. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Service Provider, 2021-2034
13.1.7. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Application, 2021-2034
13.1.8. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Testing Setting, 2021-2034
13.1.9. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts by country, 2021-2034
13.2. Europe
13.2.1. Europe Genomic Cancer Testing Market revenue in US$ Million By Technology, 2021-2034
13.2.2. Europe Genomic Cancer Testing Market revenue in US$ Million By Test Type, 2021-2034
13.2.3. Europe Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, 2021-2034
13.2.4. Europe Genomic Cancer Testing Market revenue in US$ Million By End-User, 2021-2034
13.2.5. Europe Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, 2021-2034
13.2.6. Europe Genomic Cancer Testing Market revenue in US$ Million By Service Provider, 2021-2034
13.2.7. Europe Genomic Cancer Testing Market revenue in US$ Million By Application, 2021-2034
13.2.8. Europe Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, 2021-2034
13.2.9. Europe Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034
13.3. Asia Pacific
13.3.1. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Technology, 2021-2034
13.3.2. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Test Type, 2021-2034
13.3.3. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, 2021-2034
13.3.4. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By End-User, 2021-2034
13.3.5. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, 2021-2034
13.3.6. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Service Provider, 2021-2034
13.3.7. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Application, 2021-2034
13.3.8. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, 2021-2034
13.3.9. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034
13.4. Latin America
13.4.1. Latin America Genomic Cancer Testing Market revenue in US$ Million By Technology, (US$ Million) 2021-2034
13.4.2. Latin America Genomic Cancer Testing Market revenue in US$ Million By Test Type, (US$ Million) 2021-2034
13.4.3. Latin America Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, (US$ Million) 2021-2034
13.4.4. Latin America Genomic Cancer Testing Market revenue in US$ Million By End-User, (US$ Million) 2021-2034
13.4.5. Latin America Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, (US$ Million) 2021-2034
13.4.6. Latin America Genomic Cancer Testing Market revenue in US$ Million By Service Provider, (US$ Million) 2021-2034
13.4.7. Latin America Genomic Cancer Testing Market revenue in US$ Million By Application, (US$ Million) 2021-2034
13.4.8. Latin America Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, (US$ Million) 2021-2034
13.4.9. Latin America Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034
13.5. Middle East & Africa
13.5.1. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Technology, (US$ Million) 2021-2034
13.5.2. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Test Type, (US$ Million) 2021-2034
13.5.3. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, (US$ Million) 2021-2034
13.5.4. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By End-User, (US$ Million) 2021-2034
13.5.5. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, (US$ Million) 2021-2034
13.5.6. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Service Provider, (US$ Million) 2021-2034
13.5.7. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Application, (US$ Million) 2021-2034
13.5.8. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, (US$ Million) 2021-2034
13.5.9. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034
Chapter 14. Competitive Landscape
14.1. Major Mergers and Acquisitions/Strategic Alliances
14.2. Company Profiles
14.2.1. Illumina, Inc.,
14.2.2. Thermo Fisher Scientific, Inc.,
14.2.3. Qiagen N.V.,
14.2.4. F. Hoffmann-La Roche Ltd.,
14.2.5. Foundation Medicine, Inc. (Roche),
14.2.6. Invitae Corporation,
14.2.7. NeoGenomics Laboratories, Inc.,
14.2.8. Myriad Genetics, Inc.,
14.2.9. Genomic Health, Inc. (Exact Sciences Corporation),
14.2.10. Caris Life Sciences,
14.2.11. ArcherDX, Inc. (Invitae Corporation),
14.2.12. Guardant Health, Inc.,
14.2.13. Personal Genome Diagnostics Inc.,
14.2.14. Biocept, Inc.,
14.2.15. Tempus Labs, Inc.
14.2.16. Danaher
14.2.17. PerkinElmer
14.2.18. Agilent Technologies, Inc
14.2.19. Quest Diagnostics
14.2.20. Luminex Corporation
14.2.21. Others
Genomic Cancer Testing Market By Test Type-
Genomic Cancer Testing Market By Cancer Type-
Genomic Cancer Testing Market By Technology-
Genomic Cancer Testing Market By End-User-
Genomic Cancer Testing Market By Biomarker Type-
Genomic Cancer Testing Market By Service Provider-
Genomic Cancer Testing Market By Application-
Genomic Cancer Testing Market By Testing Setting-
Genomic Cancer Testing Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
